Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ArsanisInc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ArsanisInc
-
We are excited to announce that we have entered into a definitive merger agreement with X4 Pharmaceuticals. Join our conference call at 8:30 a.m. ET. The live webcast can be accessed here: https://bit.ly/2PYbN4D pic.twitter.com/NondWL8oUh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced our Q3 2018 earnings. Read more here: https://bit.ly/2OxVOEY pic.twitter.com/lNQl1QXH4t
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced our Q2 2018 earnings. Read more here: http://bit.ly/2MkKleU pic.twitter.com/2mpEZ5oFIb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Team Arsanis had a blast yesterday at the Dragon Boat Race with
@GenoceaBio@ironwoodpharma@MorphicTx to support@LS_Cares by addressing the impact of poverty and inequality. Donations are still being accepted until tomorrow!#fundraiser#lifesciences http://lifesciencecares.org pic.twitter.com/jYTrshZQjO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Arsanis proslijedio/la je Tweet
One week from today, teams from
@ironwoodpharma@ArsanisInc@MorphicTx@GenoceaBio will compete in DRAGON BOAT RACES to raise money for Life Science Cares. Place your bets now! http://lifesciencecares.org/battle-of-boats/ …pic.twitter.com/C1XnD79mcr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We're approaching
#superbugs and#antibioticresistance with novel science. Read more about our programs: http://bit.ly/2JIr4iZHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our team is dedicated to delivering a new way to address critical infectious disease threats.
#mAbs http://bit.ly/2LNk1GqHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
According to
@CDCgov, more than 2 million people annually become infected with antibiotic-resistant bacteria, and more than 23,000 patients die as a direct result of these infections. We're working on new ways to prevent and treat these serious infections. http://bit.ly/2LxSNDIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our lead program offers a novel, non-antibiotic approach to the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. Read more about our programs and pipeline: https://bit.ly/2IPvszC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ventilator-associated pneumonia places a significant burden on patients & the healthcare system, increasing costs by approx $40K per patient. Read about our targeted prevention approach, which could profoundly impact patient outcomes & healthcare spending. http://bit.ly/2JD9qkH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Advances in our knowledge of bacterial pathogenesis have now opened new possibilities of expanding the use of
#mAbs to acute bacterial infections. Learn more about our pipeline and approach: http://bit.ly/2JIr4iZHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#FactFriday: Methicillin-resistant Staphylococcus aureus (MRSA), a.k.a the "superbug," is considered one of the top drug-resistant threats in the U.S., causing more than 11,000 deaths per year, according to@CDCgov http://bit.ly/2JLwUQKHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced the outlicensing of our preclinical stage klebsiella pneumoniae monoclonal antibodies from our ASN300 program. Read more here: http://bit.ly/2lcDepv pic.twitter.com/JuPw5GO7VQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us for our presentation at "Understanding the Development Challenges Associated with Emerging Non-Traditional Antibiotics Conference" today in Washington, DC.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are developing monoclonal antibodies, or
#mAbs, to address specific bacterial and viral pathogens without the use of antibiotics. Learn more about our novel approach: http://bit.ly/2LxSNDIHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Attending the
#ASMicrobe meeting in Atlanta this week? Hear Adriana Badarau's Oral Presentation: 3 - Characterization of A Spa/Sbi Cross-Reactive Human Monoclonal Antibody that is Protective against Staphylococcus aureus Bacteremia/Sepsis from 3:30-3:45pm ET#microbiologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Attending the
#ASMicrobe meeting in Atlanta this week? See Nikolina Trstenjak's Poster Presentation #145 - Adaptation of the Human-Specific S. Aureus Leukocidin, Lukgh, to Rabbits by Protein Engineering from 12:45-2:45pm ET#microbiology http://bit.ly/2HuIJsHHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Attending the
#ASMicrobe meeting in Atlanta this week? Hear Nikolina Trstenjak's Rapid Fire Talk 9 - Adaptation of the Human-Specific S. Aureus Leukocidin, Lukgh, to Rabbits by Protein Engineering at 2:05pm ET#microbiology http://bit.ly/2HuIJsHHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don't miss our Chief Development Officer, David Mantus, as he joins the
#BIO2018 New Development Strategies for Vaccines and Therapeutics for the Developing World panel today at 3:00 p.m. https://bit.ly/2kRUbFUHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our Head of Business Development, Aaron Pelta, will share a corporate overview at the 25th BIO Annual Meeting in Boston today at 11:30 a.m.
#BIO2018https://bit.ly/1iUmbxVHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.